Ganga Pharmaceuticals appoints auditor for FY 2026-27

1 min read     Updated on 21 May 2026, 07:07 PM
scanx
Reviewed by
Ashish TScanX News Team
AI Summary

Ganga Pharmaceuticals Limited has appointed M/s. D Maurya & Associates as its Secretarial Auditor for FY 2026-27 following a Board meeting on May 21, 2026. The firm, led by Mr. Dhirendra Maurya, brings expertise in SEBI LODR compliance and company law advisory.

powered bylight_fuzz_icon
40916237

*this image is generated using AI for illustrative purposes only.

Ganga Pharmaceuticals Limited has appointed M/s. D Maurya & Associates as its Secretarial Auditor for the financial year 2026-27. The decision was approved by the company's Board of Directors during a meeting held on May 21, 2026, based on the recommendation of the Audit Committee.

The appointment was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The firm, led by Mr. Dhirendra Maurya, a Practicing Company Secretary, will oversee the secretarial audit compliance for the company.

Details of the Appointment

The Board Meeting, which commenced at 03:30 p.m. and concluded at 4:00 p.m., sanctioned the appointment. The tenure for the auditor covers the financial year 2026-27. The disclosure regarding this change has been made in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Profile of the Auditor

M/s. D Maurya & Associates is a Mumbai-based proprietary firm established in 2010. Mr. Dhirendra Maurya, the proprietor, is an Associate Member of the Institute of Company Secretaries of India (ICSI) with Membership No. 22005. He holds a Certificate of Practice No. 9594 and a Peer Review Certificate 2544/2022.

Particulars Details
Reason for Change Appointment
Date of Appointment May 21, 2026
Firm M/s. D Maurya & Associates
Proprietor Mr. Dhirendra Maurya
Tenure Financial Year 2026-27
C.P. No. 9594
Peer Review Certificate 2544/2022

The company confirmed that there are no relationships to disclose between the directors of Ganga Pharmaceuticals Limited and the newly appointed auditor. The information is available on the company's website.

Historical Stock Returns for Ganga Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%+1.69%-17.81%+100.00%

How might the appointment of a new secretarial auditor impact Ganga Pharmaceuticals' upcoming regulatory compliance disclosures and governance ratings?

What were the findings of the previous secretarial auditor, and could any unresolved compliance issues influence the company's stock performance in FY 2026-27?

Could this governance change signal broader strategic restructuring at Ganga Pharmaceuticals, such as leadership transitions or potential mergers and acquisitions?

like18
dislike

Ganga Pharmaceuticals Appoints Deepak Jedhe & Co as Internal Auditor

1 min read     Updated on 21 May 2026, 06:57 PM
scanx
Reviewed by
Riya DScanX News Team
AI Summary

Ganga Pharmaceuticals Limited has appointed M/s. Deepak Jedhe & Co as its Internal Auditor for FY 2026-27 following a Board meeting on May 21, 2026. The firm, founded in 2015, specializes in Assurance, Taxation, and Advisory services. The appointment was based on the Audit Committee's recommendation.

powered bylight_fuzz_icon
40915643

*this image is generated using AI for illustrative purposes only.

Ganga Pharmaceuticals Limited has appointed M/s. Deepak Jedhe & Co as its Internal Auditor for the financial year 2026-27. The decision was taken by the Board of Directors during its meeting held on May 21, 2026, following the recommendation of the Audit Committee.

Appointment Details

The appointment is effective immediately, covering the upcoming financial year. M/s. Deepak Jedhe & Co, a firm of Chartered Accountants, will assume the responsibilities of Internal Auditor to ensure compliance and robust internal controls within the organization.

Auditor Profile

M/s. Deepak Jedhe & Co is a professional firm established in 2015. It provides a range of services including Assurance, Taxation, and Advisory. The firm is backed by over a decade of experience and emphasizes strong professional ethics and technical expertise to deliver value-driven solutions to its clients.

Key Information

Particulars Details
Reason for Change Appointment
Date of Appointment May 21, 2026
Tenure Financial Year 2026-27
Firm Name M/s. Deepak Jedhe & Co
Specialization Assurance, Taxation, Advisory

The Board meeting commenced at 03:30 p.m. and concluded at 4:00 p.m. on the same day. The disclosure regarding this appointment has been made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Historical Stock Returns for Ganga Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
0.0%0.0%0.0%+1.69%-17.81%+100.00%

What specific internal control weaknesses or compliance gaps at Ganga Pharmaceuticals prompted the Audit Committee to recommend a change in internal auditor for FY 2026-27?

How might M/s. Deepak Jedhe & Co's advisory and taxation expertise influence Ganga Pharmaceuticals' financial restructuring or tax optimization strategies in the coming year?

Will the appointment of a relatively newer audit firm (established 2015) impact investor confidence in Ganga Pharmaceuticals' governance standards compared to larger, more established audit firms?

like18
dislike

More News on Ganga Pharmaceuticals

1 Year Returns:-17.81%